312 related articles for article (PubMed ID: 37325970)
21. Tumour location and efficacy of first-line EGFR inhibitors in
Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
[TBL] [Abstract][Full Text] [Related]
22. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.
Ten Hoorn S; Mol L; Sommeijer DW; Nijman L; van den Bosch T; de Back TR; Ylstra B; van Dijk E; van Noesel CJM; Reinten RJ; Nagtegaal ID; Koopman M; Punt CJA; Vermeulen L
Clin Colorectal Cancer; 2023 Mar; 22(1):67-75. PubMed ID: 36564280
[TBL] [Abstract][Full Text] [Related]
23. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
24. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.
You XH; Jiang YH; Fang Z; Sun F; Li Y; Wang W; Xia ZJ; Wang XZ; Ying HQ
ESMO Open; 2020 Mar; 4(Suppl 2):. PubMed ID: 32132090
[TBL] [Abstract][Full Text] [Related]
26. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
27. Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in
Qin S; Liu T; Xu J; Li Q; Cheng Y; Zhang A; Esser R; Chang H; Li J
Future Oncol; 2023 May; 19(15):1053-1061. PubMed ID: 37017100
[TBL] [Abstract][Full Text] [Related]
28. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
29. Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study.
Kim JH; Cha Y; Shin SJ; Park YS; Kang JH; Kim C; Lim SH; Kang MJ; Kim JG; Hwang IG; Choi JK; Shin SH; Kang SY; Lee SC; Lim ST; Kim JS; Jeung HC; Kang MH; Choi IS; Ryu HW; Lee KH; Lee MH; Lee JY; Park JH; Jeon SY; Lee N; Park CY; Kim YH
Anticancer Res; 2024 Jan; 44(1):347-359. PubMed ID: 38160001
[TBL] [Abstract][Full Text] [Related]
30. Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
Kang S; Lee MW; Song IC; Lee HJ; Yun HJ; Jo DY; Kim JS; Kwon JH; Kim JY; Lee KH; Ryu H
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7819-7829. PubMed ID: 37031435
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
Marques RP; Godinho AR; Heudtlass P; Pais HL; Quintela A; Martins AP
J Cancer Res Clin Oncol; 2020 May; 146(5):1321-1334. PubMed ID: 32144533
[TBL] [Abstract][Full Text] [Related]
32. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
33. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
34. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
[TBL] [Abstract][Full Text] [Related]
35. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
36. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
37. Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States.
Nevala-Plagemann C; Iyengar S; Trunk AD; Pappas L; Haaland B; Garrido-Laguna I
J Natl Compr Canc Netw; 2022 Feb; 20(3):268-275. PubMed ID: 35120306
[TBL] [Abstract][Full Text] [Related]
38. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.
Rebersek M; Mesti T; Boc M; Ocvirk J
Radiol Oncol; 2019 Mar; 53(1):85-95. PubMed ID: 30840593
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
Yin J; Cohen R; Jin Z; Liu H; Pederson L; Adams R; Grothey A; Maughan TS; Venook A; Van Cutsem E; Punt C; Koopman M; Falcone A; Tebbutt NC; Seymour MT; Bokemeyer C; Rubio ED; Kaplan R; Heinemann V; Chibaudel B; Yoshino T; Zalcberg J; Andre T; De Gramont A; Shi Q; Lenz HJ
J Natl Cancer Inst; 2021 Nov; 113(12):1705-1713. PubMed ID: 34061178
[TBL] [Abstract][Full Text] [Related]
40. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
